Andson Biotech is a startup company, as evidenced by its small team size and recent participation in Y Combinator's W22 batch. The company is also primarily engaged in the development and use of mass spectrometry technology, as indicated by its development of the DynaCHIP technology for rapid intracellular mass spectrometry and its research publications on microfluidics enabled multi-omics triple-shot mass spectrometry for cell-based therapies.
Sapient is a startup company that provides multi-omics services, including metabolomics, lipidomics, and proteomics data generation and analysis, utilizing high-throughput mass spectrometry systems.
Rapid Novor is a startup company founded in 2015 and is primarily engaged in the development and use of mass spectrometry technology for antibody discovery and characterization services.
InterVenn is a startup company founded in 2017 and is primarily engaged in the development and use of mass spectrometry technology, specifically liquid chromatography-tandem mass spectrometry (LC-MS/MS) for glycoproteomic analysis.
908 Devices is a startup company that employs microscale mass spectrometry technology in its handheld and desktop devices for chemical and biochemical analysis.
AmberGen is a startup company that is primarily engaged in the development and use of mass spectrometry technology. The company offers Miralys Photocleavable Mass-Tag Imaging technology to enhance mass spectrometry imaging capabilities and provides products that enable multiomic imaging using mass spectrometry. Additionally, the company collaborates with Bruker on spatial biology imaging reagents for MALDI-Immunohistochemistry (MALDI-IHC).
ATONARP is a startup company that develops advanced mass spectrometry and optical spectroscopy platforms for digital molecular profiling across various industries.
Digistain is a startup company (Y-Combinator batch S21) that combines infrared multi-spectral imaging (spectrometry) with artificial intelligence for breakthrough in biomarker analysis, specifically in the field of breast cancer diagnostics.
Cancel
